Video

Dr. Vogelzang Discusses Cabozantinib's Dose Size

Author(s):

Nicholas J. Vogelzang, MD

Dr. NJ Vogelzang from the Comprehensive Cancer Centers of Nevada Discusses Cabozantinib's Dose Size

Nicholas J. Vogelzang, MD, head of the Genitourinary Cancer Section at the Comprehensive Cancer Centers of Nevada discusses the cabozantinib (XL184) dose size concerns, the drug accumulation effect that occurs, and alternative dosing strategies.

Related Videos
Byoung Chol Cho, MD, PhD, professor, internal medicine, Division of Medical Oncology, Yonsei Cancer Center, Yonsei University College of Medicine
Stephen J. Freedland, MD
Viktor Grünwald, MD, PhD
Aaron Gerds, MD
Christine M. Lovly, MD, PhD, Ingram Associate Professor of Cancer Research, associate professor, medicine (hematology/oncology), Vanderbilt-Ingram Cancer Center
Haeseong Park, MD, MPH
David L. Porter, MD
Timothy Yap, MBBS, PhD, FRCP
Leo I. Gordon, MD, Abby and John Friend Professor of Oncology Research, professor, medicine (hematology and oncology), Feinberg School of Medicine, Robert H. Lurie Cancer Center
Related Content
Giuseppe Curigliano, MD, PhD
June 2nd 2024

Trastuzumab Deruxtecan Prolongs PFS in Pretreated HR+, HER2-Low and -Ultralow Metastatic Breast Cancer

Stephen Liu, MD; Sara A. Hurvitz, MD, FACP; S. Vincent Rajkumar, MD; Sumanta Kumar Pal, MD, FASCO; Shubham Pant, MD, MBBS
May 23rd 2024

Oncology Experts Preview Top Abstracts From the 2024 ASCO Annual Meeting

Kevin Kalinsky, MD, MS, of Winship Cancer Institute
June 2nd 2024

Abemaciclib/Fulvestrant Boosts PFS in HR+/HER2– Breast Cancer Post–CDK4/6i Progression

OncLive On Air
March 18th 2024

Revisit the OncLive On Air Episodes From February 2024

Joyce O'Shaughnessy, MD
June 1st 2024

Anthracycline Plus Chemo Associated With Improved RFS in MP High-2–Risk, HR+/HER2– Early Breast Cancer

Here is your guide to important regulatory approvals made by the FDA in May 2024.
May 31st 2024

OncLive’s May Roundup of Key FDA Approvals in Oncology